Table 3. Univariate and multivariate analysis predicting the probability of Gleason sum ≥7 at pathologic staging.
| Predictors | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| AUC of individual predictor variables | OR; p-value | Base model OR; p-value | Base model with %p2PSA; p-value | Base model with PHI; p-value | |
| Age | 0.445 | 0.989; 0.623 | |||
| Prostate volume | 0.491 | 0.889; 0.723 | |||
| Clinical stage | 0.698 | 23.109; <0.001 | 43.924; <0.001 | 72.612; <0.001 | 1982.218; <0.001 |
| Percentage of positive biopsy core | 0.637 | 3.251; 0.021 | 7.421; <0.001 | 14.861; <0.001 | 22.176; <0.001 |
| PSA density | 0.582 | 1.023; 0.124 | |||
| tPSA | 0.714 | 1.180; <0.001 | 1.312; 0.038 | 1.612; 0.007 | 0.991; 0.968 |
| fPSA | 0.570 | 1.060; 0.611 | |||
| %fPSA | 0.287 | 0.001; <0.001 | 0.231; 0.845 | 8.239; 0.616 | 0.052; 0.790 |
| p2PSA | 0.754 | 1.063; <0.001 | |||
| %p2PSA | 0.836 | 10.557; <0.001 | |||
| PHI | 0.849 | 1.243; <0.001 | |||
| AUC of multivariate models | 0.861 | 0.901 | 0.932 | ||
| Gain in predictive accuracy (%, p-value) | 4.0% (<0.001) | 7.1% (<0.001) | |||
AUC, area under the curve; OR, odds ratio; PHI, prostate health index; PSA, prostate-specific antigen; tPSA, total PSA; fPSA, free PSA; %fPSA, the percentage of free PSA to total PSA; %p2PSA, the percentage of p2PSA to free PSA.
The AUC reflects the predictive values of individual variables (columns) and of the multivariate models for predicting the probability of Gleason sum ≥7.